Class / Patent application number | Description | Number of patent applications / Date published |
514190600 | Leukemia | 32 |
20110118193 | TREATMENT OF LIQUID CANCERS - A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount. | 05-19-2011 |
20110144033 | Proteasome Inhibitors and Methods of Using the Same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 06-16-2011 |
20110183918 | Method of Treating Leukemia Using Rcie Prolamin - The present invention relates to a method of treating leukemia using rice prolamin, and a pharmaceutical composition for treating leukemia, comprising an effective amount of rice prolamin together with one or more pharmaceutically acceptable carriers or excipients. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (PBMC) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia U937 cells. The rice prolamin is gluten-free, thus will not trigger gastrointestinal allergic reaction. | 07-28-2011 |
20110190219 | TREATING CANCER WITH GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR - Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described. | 08-04-2011 |
20110190220 | Use of Defensin Alpha 1 and/or Defensin Alpha 4, as a Marker for Predicting Treatment Response and/or a Relapse in a Patient Suffering form Chronic Myeloid Leukemia - The present invention pertains to the use of defensin α1 and/or defensin α4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib. | 08-04-2011 |
20110230422 | PURGING OF AN EX VIVO HEMATOPOIETIC STEM CELL CULTURE OF CANCER CELLS - A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in an effective amount. | 09-22-2011 |
20120021999 | PRO-APOPTOTIC PEPTIDES - The invention relates to chimeric peptides useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors. | 01-26-2012 |
20120094926 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-19-2012 |
20120149647 | Methods for Assessing the Efficacy of Gemcitabine or Ara-C Treatment of Cancer Using Human Antigen R Levels - Disclosed are compositions and methods relating to the treatment of a disease with a nucleoside analog, such as gemcitabine or Ara-C, and a polynucleotide construct encoding for an mRNA binding protein, such as Human antigen R. | 06-14-2012 |
20120172315 | Peptides Used for Treating Cancers and, in Particular, Chronic Lymphoid Leukaemia - The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia. | 07-05-2012 |
20120264697 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS - The present invention relates to treating a hematologic cancer using a Hypoxia- Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor. | 10-18-2012 |
20120270802 | BINDING MOLECULES FOR THE TREATMENT OF MYELOID CELL MALIGNANCIES - Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention, and/or treatment of neoplastic disorders and diseases. | 10-25-2012 |
20120277164 | GADD45BETA TARGETING AGENTS - Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders. | 11-01-2012 |
20120322742 | THERAPEUTICS TO INHIBIT MLL-MENIN INTERACTION FOR TREATING LEUKEMIA - Cell permeable peptides derived from MLL that block the interaction of MLL with menin for the treatment of acute myeloid and acute lymphoid leukemia are disclosed. Small molecules interfere with the interaction of MLL with any of its binding partners. | 12-20-2012 |
20130157961 | LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE - The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu. | 06-20-2013 |
20130190251 | METHOD FOR PREDICTING THE RESPONSIVENESS TO CHEMOTHERAPY - The present invention concerns a method for predicting the responsiveness of an individual suffering from leukemia to a chemotherapeutic drug. In particular, this method comprises determining the proportion of leukemic cells expressing cytoplasmic PCNA in a biological sample of the individual. The present invention also relates to a tyrosine kinase inhibitor for use for the treatment of an individual suffering from leukemia and having a proportion of leukemic cells expressing cytoplasmic PCNA in a biological sample lower than a predetermined threshold. The invention also pertains to a method for diagnosing whether an individual suffers, or is at risk of suffering, from leukemia. | 07-25-2013 |
20140066386 | THERAPIES FOR HEMATOLOGIC MALIGNANCIES - The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, | 03-06-2014 |
20140073585 | PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE - Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL. | 03-13-2014 |
20140073586 | Compositions for the treatment of cancer, and methods for testing and using the same - A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells. Also provided is a method of selectively inducing cell death in myeloid leukocytes. The method comprises contacting the myeloid leukocytes with a composition comprising leukotoxin proteins. These leukotoxin proteins may be isolated from the NJ4500 strain of | 03-13-2014 |
20140206624 | TREATMENT OF LEUKEMIA - Compositions and methods for the treatment of leukemia by inhibiting FOXO signaling are described. | 07-24-2014 |
20150031627 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here. | 01-29-2015 |
20150051156 | METHOD OF TREATING LEUKEMIA USING RICE PROLAMIN - The present invention relates to a method of treating leukemia using rice prolamin, comprising administering a daily dose of isolated prolamin to a patient suffering from leukemia for a period of time from 5 days to 10 days. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (PBMC) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia cells. The rice prolamin is gluten-free, thus will not trigger gastrointestinal allergic reaction, it also can decrease the tumor weight without changes in body weight and can inhibit the growth of peripheral blood leukocyte in leukemia mouse model. | 02-19-2015 |
20150080317 | TEMPLATE-FIXED PEPTIDOMIMETICS - The template-fixed B-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala- | 03-19-2015 |
20150087600 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here. | 03-26-2015 |
20150126456 | Method and Pharmaceutical Composition for use in the Treatment of Cancer - The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier. | 05-07-2015 |
20150368300 | COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS - The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia. | 12-24-2015 |
20160039908 | Method and Pharmaceutical Composition for use in the Treatment of Cancer - The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier. | 02-11-2016 |
20160082071 | METHODS OF TREATING MYELOID LEUKEMIA - There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent. | 03-24-2016 |
20160122405 | HOMEODOMAIN FUSION PROTEINS AND USES THEREOF - Provided herein are fusion proteins comprising a homeodomain fusion protein domain and a transcription modulator domain for treatment of various diseases or disorders such as cancer. The homeodomain fusion protein domain binds to a target gene and the transcription modulator domain either activates or represses gene transcription. The present invention also relates to polynucleotides encoding the fusion proteins, vectors comprising the polynucleotides, cells comprising the polynucleotides, vectors, or fusion proteins. Also provided are methods of use and compositions for delivery of the fusion proteins. | 05-05-2016 |
20160130298 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here. | 05-12-2016 |
20160161495 | Method of Treatment - A method of diagnosing and treating proliferative disorders in connection with the use of a Smac mimetic. | 06-09-2016 |
20170233819 | Method and Therapeutic Use of PIGN and Other Genes or Gene Products That PIGN Interacts With for Prognosis and Treatment of Hematological Neoplasias | 08-17-2017 |